{"generic":"Ethinyl Estradiol\/Levonorgestrel","drugs":["Alesse","Alesse-28","Altavera","Amethia","Amethia Lo","Aviane","Camrese","CamreseLo","Ethinyl Estradiol\/Levonorgestrel"],"mono":[{"id":"337215-s-0","title":"Generic Names","mono":"Ethinyl Estradiol\/Levonorgestrel"},{"id":"337215-s-1","title":"Dosing and Indications","sub":{"0":{"id":"337215-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Contraception:<\/b> Alesse(R), 1 pink tablet ORALLY daily for 21 consecutive days; then take 1 green inert tablet ORALLY daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Lybrel(TM), 1 tablet ORALLY daily without any tablet-free interval<\/li><li><b>Contraception:<\/b> Quartette(TM), 1 light pink tablet ORALLY daily for 42 consecutive days starting the first Sunday after onset of menstruation; then 1 pink tablet ORALLY daily for 21 days; then 1 purple tablet ORALLY once daily for 21 days; then 1 yellow tablet ORALLY once daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> Seasonale(R), 1 pink active tablet ORALLY daily for 84 consecutive days, followed by 7 days of white inactive tablets; repeat cycle<\/li><\/ul>"},"1":{"id":"337215-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy before menarche have not been established<\/li><li><b>Contraception:<\/b> after menarche: Alesse(R), 1 pink tablet ORALLY daily for 21 consecutive days; then 1 green inert tablet ORALLY daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> after menarche: Lybrel(TM), 1 tablet ORALLY daily without any tablet-free interval<\/li><li><b>Contraception:<\/b> after menarche: Quartette(TM), 1 light pink tablet ORALLY daily for 42 consecutive days starting on the first Sunday after onset of menstruation; then 1 pink tablet ORALLY daily for 21 days; then 1 purple tablet ORALLY once daily for 21 days; then 1 yellow tablet ORALLY once daily for 7 days; repeat cycle<\/li><li><b>Contraception:<\/b> after menarche: Seasonale(R), 1 pink active tablet ORALLY daily for 84 consecutive days, followed by 7 days of white inactive tablets; repeat cycle<\/li><\/ul>"},"3":{"id":"337215-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Contraception<br\/>"}}},{"id":"337215-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women older than 35 years, and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.<br\/>"},{"id":"337215-s-3","title":"Contraindications\/Warnings","sub":[{"id":"337215-s-3-9","title":"Contraindications","mono":"<ul><li>carcinoma of the breast, known, suspected, or personal history<\/li><li>carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia  or progestin-sensitive cancer, current or past<\/li><li>cerebrovascular or coronary artery disease, current or past history<\/li><li>cholestatic jaundice of pregnancy or jaundice with prior pill use<\/li><li>deep vein thrombophlebitis or thromboembolic disorders (eg, pulmonary embolism), current  or history of<\/li><li>diabetes with vascular disease<\/li><li>genital bleeding, undiagnosed, abnormal<\/li><li>headaches with focal neurological symptoms<\/li><li>hepatic adenomas or carcinomas  or other liver tumors, benign or malignant<\/li><li>hypersensitivity to any of the product components<\/li><li>hypertension, uncontrolled<\/li><li>liver disease, active<\/li><li>major surgery with prolonged immobilization (Falmina(TM), Jolessa(R))<\/li><li>migraines with or without aura and older than 35 years (Daysee(TM), Quartette(TM))<\/li><li>pregnancy, known or suspected<\/li><li>smoking and older than 35 years (Daysee(TM), Quartette(TM))<\/li><li>thrombogenic rhythm disorders<\/li><li>thrombophilias, hereditary or acquired<\/li><li>thrombophlebitis or thromboembolic disorders<\/li><li>valvular heart disease with thrombogenic complications<\/li><\/ul>"},{"id":"337215-s-3-10","title":"Precautions","mono":"<ul><li>cigarette smoking; increased risk of serious cardiovascular effects, especially in women older than 35 years<\/li><li>vascular and thromboembolic disorders, including myocardial infarction, venous thrombosis\/thromboembolism, and thrombotic\/hemorrhagic strokes, may occur; increased risk with cigarette smoking and underlying cardiovascular disease risk factors (hypertension, hypercholesterolemia, morbid obesity, and diabetes); vascular disease risk may persist for several years following discontinuation<\/li><li>angioedema, hereditary; symptoms may be induced or exacerbated (Daysee(TM), Quartette(TM))<\/li><li>chloasma may occur; increased risk with history of chloasma gravidarum; avoid sun exposure or UV radiation if occurs (Daysee(TM), Quartette(TM))<\/li><li>cholestasis, history during pregnancy; increased risk for recurrence (Daysee(TM), Quartette(TM))<\/li><li>contact lens use; assess by an ophthalmologist if visual changes or changes in lens tolerance occurs<\/li><li>depression may occur; monitoring recommended in women with a history of depression; discontinue use if significant depression develops or recurs<\/li><li>dyslipidemia, uncontrolled; adverse lipid changes may occur; monitoring recommended<\/li><li>fluid retention may occur; use with caution in patients with conditions aggravated by fluid retention; monitoring recommended<\/li><li>gallbladder disease may occur or worsen<\/li><li>glucose intolerance may occur; increased risk with higher doses of estrogens (greater than 75 mcg); monitoring recommended for prediabetic and diabetic women<\/li><li>headache or migraine that is recurrent, persistent, or severe; exacerbation or new onset; discontinue and evaluate cause<\/li><li>hepatic adenomas, benign, have been reported and may be fatal if rupture occurs<\/li><li>hepatocellular carcinoma has been reported rarely; increased risk associated with long-term use (longer than 8 years)<\/li><li>hypertension may occur; increased risk with increasing quantities of progestogens and continued use; monitoring recommended and discontinue if significant elevation occurs<\/li><li>hypertriglyceridemia, current or family history; increased risk of pancreatitis<\/li><li>impaired hepatic function; metabolism of oral contraceptive may be impaired; discontinue use if jaundice develops<\/li><li>menstrual bleeding abnormalities, including breakthrough bleeding, spotting, and amenorrhea, may occur; in cases of abnormal vaginal bleeding, rule out malignancy or pregnancy with adequate diagnostic measures<\/li><li>postoperative thromboembolic complications have been reported; discontinue at least 4 weeks prior to and for 2 weeks after elective surgery, and during and following prolonged immobilization<\/li><li>postpartum period; increased risk of thromboembolism; initiate no sooner than 4 weeks after delivery (in women who are not breastfeeding) or after midtrimester termination of pregnancy<\/li><li>retinal vein thrombosis has been reported; discontinue use if unexplained partial or complete loss of vision, diplopia, proptosis, papilledema, or retinal vascular lesions develop<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"337215-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"337215-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding if possible.  May inhibit lactation.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},{"id":"337215-s-4","title":"Drug Interactions","sub":[{"id":"337215-s-4-13","title":"Contraindicated","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Ombitasvir (established)<\/li><li>Paritaprevir (established)<\/li><li>Ritonavir (theoretical)<\/li><li>Tranexamic Acid (probable)<\/li><\/ul>"},{"id":"337215-s-4-14","title":"Major","mono":"<ul><li>Anagrelide (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Felbamate (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paclitaxel Protein-Bound (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pirfenidone (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (probable)<\/li><li>Ulipristal (established)<\/li><\/ul>"},{"id":"337215-s-4-15","title":"Moderate","mono":"<ul><li>Acitretin (probable)<\/li><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Eslicarbazepine Acetate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Lamotrigine (established)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Perampanel (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Roflumilast (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Tacrine (probable)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Valdecoxib (probable)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"337215-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Acne<\/li><li><b>Endocrine metabolic:<\/b>Weight increased<\/li><li><b>Gastrointestinal:<\/b>Nausea and vomiting<\/li><li><b>Neurologic:<\/b>Headache, Migraine<\/li><li><b>Psychiatric:<\/b>Anxiety, Depression, Mood swings, Panic attack<\/li><li><b>Reproductive:<\/b>Break-through bleeding, Breast tenderness, Dysmenorrhea, Pain of breast<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Myocardial infarction<\/li><li><b>Gastrointestinal:<\/b>Cholecystitis, Cholelithiasis, Disorder of gallbladder, Pancreatitis<\/li><li><b>Hematologic:<\/b>Arterial thrombosis, Deep venous thrombosis, Pulmonary thrombosis, Thrombosis<\/li><li><b>Hepatic:<\/b>Abnormal liver function, Benign neoplasm of liver, Neoplasm of liver<\/li><li><b>Neurologic:<\/b>Hemorrhagic cerebral infarction, Thrombotic stroke<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><li><b>Psychiatric:<\/b>Suicidal behavior<\/li><li><b>Reproductive:<\/b>Ectopic pregnancy, Miscarriage<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><li><b>Other:<\/b>Angioedema, Neoplasm of liver<\/li><\/ul>"},{"id":"337215-s-6","title":"Drug Name Info","sub":{"0":{"id":"337215-s-6-17","title":"US Trade Names","mono":"<ul><li>Alesse<\/li><li>Alesse-28<\/li><li>Altavera<\/li><li>Amethia<\/li><li>Amethia Lo<\/li><li>Aviane<\/li><li>Camrese<\/li><li>CamreseLo<\/li><\/ul>"},"2":{"id":"337215-s-6-19","title":"Class","mono":"<ul><li>Contraceptive<\/li><li>Estrogen<\/li><li>Monophasic Contraceptive Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"337215-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"337215-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"337215-s-7","title":"Mechanism Of Action","mono":"Ethinyl estradiol and levonorgestrel are contraceptives that suppress gonadotropins. In combination it primarily prevents ovulation and induces changes in the endometrium and cervical mucus to decrease the possibility of fertilization and implantation.<br\/>"},{"id":"337215-s-8","title":"Pharmacokinetics","sub":[{"id":"337215-s-8-23","title":"Absorption","mono":"<ul><li>Ethinyl estradiol, Oral: time to peak concentration, 1.3 h +\/- 0.7 h<\/li><li>Ethinyl estradiol, Bioavailability: 38% to 48%<\/li><li>Levonorgestrel, Oral: time to peak concentration, 1.5 h +\/- 0.5 h to 1.6 h +\/- 0.9 h<\/li><li>Levonorgestrel, Bioavailability: about 100%<\/li><\/ul>"},{"id":"337215-s-8-24","title":"Distribution","mono":"<ul><li>Ethinyl estradiol, Vd: 12.4 L\/kg +\/- 4.1 L\/kg to 15.5 L\/kg +\/- 4 L\/kg<\/li><li>Ethinyl estradiol, Protein binding: about 97%<\/li><li>Levonorgestrel, Vd: 1.43 L\/kg +\/- 0.62 L\/kg to 2.66 L\/kg +\/- 1.09 L\/kg<\/li><li>Levonorgestrel, Protein binding: primarily bound to sex hormone binding globulin<\/li><\/ul>"},{"id":"337215-s-8-25","title":"Metabolism","mono":"<ul><li>Ethinyl estradiol-Hepatic and Gut; P450 CYP3A4; 2-hydroxylation, enterohepatic circulation<\/li><li>Metabolites: 2-hydroxy metabolite<\/li><li>Levonorgestrel; reduction, hydroxylation and conjugation<\/li><li>Metabolites: sulfates of 3 alpha, 5 beta-tetrahydro-levonorgestrel<\/li><\/ul>"},{"id":"337215-s-8-26","title":"Excretion","mono":"<ul><li>Ethinyl estradiol, Fecal and Renal: as glucuronide and sulfate conjugates<\/li><li>Levonorgestrel, Fecal: 16% to 48% unchanged and as metabolites<\/li><li>Levonorgestrel, Renal: 40% to 68% unchanged and as metabolites<\/li><\/ul>"},{"id":"337215-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Ethinyl estradiol: 18 h +\/- 4.7 h<\/li><li>Levonorgestrel: approximately 36 h +\/- 13 h<\/li><\/ul>"}]},{"id":"337215-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take exactly as directed at intervals not exceeding 24 hours<\/li><li>tablets should be taken at the same time each day<\/li><li>nonhormonal back-up method of contraception is recommended for the first 7 days after initiating the first cycle (Alesse(R), Quartette(TM), Seasonale(R)<\/li><li>nonhormonal back-up method of contraception is recommended for the first 7 days of therapy when converting from a progestin-only pill or an implantable or injectable contraceptive to Lybrel(TM)<\/li><li>nonhormonal back-up contraception should be used if the patient starts tablets later than the proper day or misses 2 or more active tablets; continue back-up contraception until the patient has taken an active tablet daily for 7 consecutive days (Alesse(R), Quartette(TM), Seasonale(R))<\/li><li>nonhormonal back-up contraception should be used if the patient misses 1 or more active tablets; continue back-up contraception until the patient has taken an active tablet daily for 7 consecutive days (Lybrel(TM))<\/li><\/ul>"},{"id":"337215-s-10","title":"Monitoring","mono":"<ul><li>annual history and physical; including blood pressure, cervical cytology and breast exam (in addition to monthly self-exam)<\/li><li>diagnostic measures to rule out malignancy in cases of undiagnosed, persistent\/recurrent abnormal vaginal bleeding<\/li><\/ul>"},{"id":"337215-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Levonorgestrel) 20 MCG-90 MCG<br\/><\/li><li><b>Amethyst<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Levonorgestrel) 20 MCG-90 MCG<br\/><\/li><li><b>Portia-28<\/b><br\/>Oral Tablet: (Ethinyl Estradiol - Levonorgestrel) 30 MCG-0.15 MG<br\/><\/li><\/ul>"},{"id":"337215-s-12","title":"Toxicology","sub":[{"id":"337215-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"337215-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"337215-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},{"id":"337215-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to practice safe sex. Drug does not prevent disease transmission.<\/li><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, thrombophlebitis, dementia, pulmonary embolism, or breast cancer.<\/li><li>This drug may cause change in weight, bloating, nausea, stomach cramps, vomiting, headache, mood swings, abnormal menstruation, amenorrhea, enlarged or tender breasts, or nipple discharge.<\/li><li>Tell patient to report persistent\/recurrent abnormal vaginal bleeding.<\/li><li>Patients should report any unexplained partial or complete loss of vision. In addition, patients who wear contact lenses should report visual changes or changes in lens tolerance.<\/li><li>This drug should be taken every day, at the same time each day with not more than 24 h between doses.<\/li><li>Advise patient to use a non-hormonal backup form of contraception for the first 7 days if a Sunday-start regimen is initiated.<\/li><li>Patients should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Review with the patient the procedure for handling missed doses. It is very important that the patient follow carefully missed-dose instructions for the particular brand or formulation prescribed in order to prevent pregnancy. In many cases, this will necessitate the use of a back-up method of contraception until the regular schedule has been reestablished.<\/li><li>If patient is still unsure of what to do in the event of a missed dose, patient should use a back-up form of contraception and contact healthcare professional for instructions.<\/li><\/ul>"}]}